Lithuania Martynas Jocys, Baltics marketing director and Lithuania general manager at AstraZeneca, talks about the role that innovation has played in the company’s strategy, the need for increased patient access in Lithuania and the other Baltic countries as well as the launch of new products for oncology, biologics, severe asthma, diabetes,…
Serbia By reorganizing their management structure, diversifying their offering and presenting an altogether cleaner image, AstraZeneca Serbia has made tremendous progress since its beginnings in the Balkans in the late 1990s. Country Director Ksenija Purkovic discusses the future of the Anglo-Swedish outfit, and how best to navigate a market that is…
Poland Jarek Oleszczuk, country president of AstraZeneca Poland, the leading R&D investor in Poland, discusses the exciting milestones that the company has achieved, including reimbursement of two breakthrough oncology therapies, as well as the company’s addition of 500 staff, representing now a 1,150-strong workforce. Furthermore, he touches on AstraZeneca’s key role…
Brazil Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors. You were appointed country president of AstraZeneca Brazil in September 2016 after…
Bulgaria Zoya Paunova, country director at AstraZeneca Bulgaria, explains how a great combination of an innovative product portfolio with a skilled and dedicated team has turned the local offering into leading brands in the Bulgarian pharmaceutical market and highlights that AstraZeneca’s CSR initiatives are now ranked as the best in Europe.…
Canada Ed Dybka, President of AstraZeneca Canada, highlights the successful ‘return to growth’ journey the affiliate has undergone in the past few years, his thoughts on the need for a renewed and modernized pharmaceutical framework agreement between industry and government, and the strong business case Canada needs to make in order…
Hong Kong Small markets must inevitably etch out a niche positioning for themselves, and for Hong Kong, its world-class medical infrastructure, world-renowned academics and clinicians as well as high population density make it a strong contender in clinical research. Hong Kong is an important piece of our global R&D landscape Scott…
Austria Ana Kostova, Austrian country president for AstraZeneca, a global powerhouse in innovative drugs and R&D, discusses the opportunities and challenges of introducing innovative treatments into the Austrian healthcare system as well as AstraZeneca´s exciting pipeline, especially in the field of oncology. She also provides an insight into the future potential…
Hong Kong Scott Curley, general manager of Astra Zeneca Hong Kong, discusses how his affiliate managed to achieve its successful product launch track record; shares his insights on the key specificities of Hong Kong and further explains why it is an important market for Astra Zeneca’s global R&D. Having previously worked extensively…
Ukraine Evgeniy Gaydukov, Country Director of AstraZeneca Ukraine, provides insights into the remarkable growth that the science-led, innovative company has been experiencing in Ukraine despite the unstable economic situation in the country, as well as the socially oriented, collaborative, and patient-centric approach he has been bolstering since taking over the helm…
Pharma After choosing Egypt as the first country to host a production plant in the Middle East, AstraZeneca is interested in strengthening its foothold in the market. The country president discusses the challenges the company is facing as well as the initiatives in place to increase market access and affordability. Could…
pharma Ileana Quiñones, president and general manager of iPR-AstraZeneca, discusses the clear strategy of the affiliate in being a leading manufacturer in Puerto Rico and the steps necessary to ensure their place in the country and within the AstraZeneca organization. Where is AstraZeneca focused today and how does the Puerto Rican…
See our Cookie Privacy Policy Here